Clinical Trial Update: CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating CTX-009 in combination with gemcitabine, cisplatin, and durvalumab as first-line therapy for unresectable or metastatic bi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• CTX-009 (CTX-009)
• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Biliary Tract Cancer | Phase 1, Phase 2 | Status: RECRUITING